Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWong, Germaineen
dc.contributor.authorHoward, K.en
dc.contributor.authorChapman, J.R.en
dc.contributor.authorTong, Allisonen
dc.contributor.authorBourke, Michaelen
dc.contributor.authorHayen, Andrewen
dc.contributor.authorMacaskill, P.en
dc.contributor.authorHope, Richarden
dc.contributor.authorWilliams, Narelleen
dc.contributor.authorKieu, Anhen
dc.contributor.authorAllen, Richarden
dc.contributor.authorChadban, Stevenen
dc.contributor.authorPollock, Carolen
dc.contributor.authorWebster, Angela Cen
dc.contributor.authorRoger, Simon Den
dc.contributor.authorCraig, J.C.en
dc.identifier.citationVolume 11, Issue 1, pp. 1-7en
dc.description.abstractBackground: Cancer is a major cause of mortality and morbidity in patients with chronic kidney disease (CKD). In patients without kidney disease, screening is a major strategy for reducing the risk of cancer and improving the health outcomes for those who developed cancers by detecting treatable cancers at an early stage. Among those with CKD, the effectiveness, the efficacy and patients’ preferences for cancer screening are unknown. Methods/Design: This work describes the protocol for the DETECT study examining the effectiveness, efficiency and patient’s perspectives of colorectal cancer screening using immunochemical faecal occult blood testing (iFOBT) for people with CKD. The aims of the DETECT study are 1) to determine the test performance characteristics of iFOBT screening in individuals with CKD, 2) to estimate the incremental costs and health benefits of iFOBT screening in CKD compared to no screening and 3) to elicit patients’ perspective for colorectal cancer screening in the CKD population. Three different study designs will be used to explore the uncertainties surrounding colorectal cancer screening in CKD. A diagnostic test accuracy study of iFOBT screening will be conducted across all stages of CKD in patients ages 35-70. Using individually collected direct healthcare costs and outcomes from the diagnostic test accuracy study, cost-utility and cost-effective analyses will be performed to estimate the costs and health benefits of iFOBT screening in CKD. Qualitative in-depth interviews will be undertaken in a subset of participants from the diagnostic test accuracy study to investigate the perspectives, experiences, attitudes and beliefs about colorectal cancer screening among individuals with CKD. Discussion: The DETECT study will target the three major unknowns about early cancer detection in CKD. Findings from our study will provide accurate and definitive estimates of screening efficacy and efficiency for colorectal cancer, and will allow better service planning and budgeting for early cancer detection in this at-risk population. The DETECT study is also registered with the Australia New Zealand Clinical Trials Registry ACTRN12611000538943en
dc.subjectKidney Diseaseen
dc.titleTest Performance of Faecal Occult Blood Testing for the Detection of Bowel Cancer in People with Chronic Kidney Disease (DETECT) Protocolen
dc.typeJournal Articleen
dc.identifier.journaltitleBioMed Central Public Healthen
dc.type.studyortrialClinical Trialen
item.openairetypeJournal Article-
item.fulltextWith Fulltext-
Appears in Collections:Renal Medicine
Files in This Item:
File Description SizeFormat 
10.1186_1471-2458-11-516.pdfWongG, 2011, Test performance of faecal occult blood testing for the detection of bowel cancer in people with chronic kidney disease (DETECT) protocol206.74 kBAdobe PDFThumbnail
Show simple item record

Page view(s)

checked on Mar 27, 2023


checked on Mar 27, 2023

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.